[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 484
Citations 0
Clinical Trials Update
August NaN, 2016

Antiviral Reduces Mother-to-Child Transmission of Hepatitis B

JAMA. 2016;316(8):809. doi:10.1001/jama.2016.11466

Treating pregnant women with the antiviral therapy tenofovir disoproxil fumarate (TDF) reduced mother-to-child transmission of hepatitis B virus (HBV), according to a recent randomized trial (Pan CQ et al. N Engl J Med. 2016; 374[24]:2324-2334). Although postnatal immunoprophylaxis by passive or active immunization can reduce the rate of mother-to-child transmission from 90% to 10%, it fails in up to 30% of infants born to mothers with an HBV DNA level of more than 6 log10 copies/mL (200 000 IU/mL). Preventing mother-to-child transmission of HBV is vital to eliminating HBV globally and reducing liver cancer, according to the authors.

First Page Preview View Large
First page PDF preview
First page PDF preview